{"id":"NCT03820726","sponsor":"Boehringer Ingelheim","briefTitle":"A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)","officialTitle":"An Open-label Extension Trial of the Long Term Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-04-16","primaryCompletion":"2022-08-30","completion":"2022-08-30","firstPosted":"2019-01-29","resultsPosted":"2023-09-13","lastUpdate":"2023-09-13"},"enrollment":435,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lung Diseases, Interstitial"],"interventions":[{"type":"DRUG","name":"Nintedanib","otherNames":[]}],"arms":[{"label":"Nintedanib","type":"EXPERIMENTAL"}],"summary":"The main objective is to assess long term tolerability and safety of treatment with oral nintedanib in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD) who have complete (and did not prematurely discontinue trial medication in) the phase III parent trial, INBUILDÂ® (trial 1199.247).","primaryOutcome":{"measure":"Number of Participants With Any Adverse Events","timeFrame":"From first nintedanib intake until last nintedanib intake + 28 days of Residual effect period (REP), up to 1195 days.","effectByArm":[{"arm":"Nintedanib","deltaMin":417,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":121,"countries":["United States","Argentina","Belgium","Canada","Chile","China","France","Germany","Italy","Japan","Poland","Russia","South Korea","Spain","United Kingdom"]},"refs":{"pmids":["39789408"],"seeAlso":["http://www.mystudywindow.com"]},"adverseEventsSummary":{"seriousAny":{"events":234,"n":434},"commonTop":["Diarrhoea","Nausea","Cough","Weight decreased","Dyspnoea"]}}